Data di Pubblicazione:
2013
Citazione:
Differential targeting of immune-cells by Pixantrone in experimental myasthenia gravis / R. Marolda, C. Ruocco, C. Cordiglieri, C. Toscani, C. Antozzi, R. Mantegazza, F. Baggi. - In: JOURNAL OF NEUROIMMUNOLOGY. - ISSN 0165-5728. - 258:1-2(2013 May 15), pp. 41-50. [10.1016/j.jneuroim.2013.02.021]
Abstract:
Pixantrone was shown to reduce the severity of clinical manifestation in experimental myasthenia gravis. In the present work we further studied its therapeutic effect. Our results demonstrate that a single administration suppressed AChR-specific immune-responses in primed rats. However, clinical symptoms could be improved only by repeated drug administrations (q7dx6 protocol-8.12 mg/kg); this treatment allowed stable serum drug levels for at least 7 days, as assessed by a functional T-cell bioassay. Pixantrone exerted strong in vitro inhibitory effect only on proliferating T-cells without impairing dendritic cell differentiation and B-cell viability. Our data further demonstrate that Pixantrone is a promising immunosuppressant drug that should be investigated in myasthenia gravis. (C) 2013 Elsevier B.V. All rights reserved.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
Pixantrone; Acetylcholine receptor (AChR); Experimental autoimmune myasthenia gravis (EAMG); Immunomodulation
Elenco autori:
R. Marolda, C. Ruocco, C. Cordiglieri, C. Toscani, C. Antozzi, R. Mantegazza, F. Baggi
Link alla scheda completa: